Login to Your Account



Despite approvals, U.S. still waiting for biosimilar market to develop

By Mari Serebrov
Regulatory Editor

Monday, September 26, 2016

Although the FDA approved its fourth biosimilar Friday – Amgen Inc.'s Amjevita, which references Abbvie Inc.'s blockbuster Humira – the U.S. is not much closer to having a truly competitive biosimilars market, as only one biosimilar has actually launched.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription